Your session is about to expire
← Back to Search
Sub Study 1 - AZD0901 MONOTHERAPY for Pancreatic Adenocarcinoma
Study Summary
This trial aims to test the safety, effectiveness, and how well the drug AZD0901 works alone or when combined with other cancer treatments in patients with advanced or spreading tumors that have a certain protein
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are researchers currently seeking participants for this ongoing medical study?
"Indeed, according to the information available on clinicaltrials.gov, this trial is actively enrolling participants. The study was initially posted on December 13th, 2023 and underwent its most recent update on January 12th, 2024."
At present, how many locations are hosting this particular clinical trial?
"This clinical trial is currently enrolling patients from a total of 26 sites. These sites are located in various cities such as Orange, Kashiwa, and Louisville, among others. If you decide to participate, it may be advantageous to choose the site closest to your location in order to minimize travel obligations."
What is the current number of individuals actively involved in this medical study?
"Indeed, as per the records on clinicaltrials.gov, this ongoing clinical trial is actively seeking individuals to participate. The study was initially posted on December 13th, 2023 and last updated on January 12th, 2024. A total of 123 patients will be enrolled across a network of 26 different locations."
Has the Food and Drug Administration officially granted approval for Sub Study 1 - AZD0901 MONOTHERAPY?
"Since this is a Phase 2 trial, there is limited safety data available for Sub Study 1 - AZD0901 monotherapy. Therefore, our team at Power rates its safety as a 2 on a scale of 1 to 3."
Share this study with friends
Copy Link
Messenger